Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

Exploring KRAS-mutant pancreatic ductal adenocarcinoma: a model validation study

IntroductionPancreatic ductal adenocarcinoma (PDAC) has the highest mortality rate among all solid tumors. Tumorigenesis is promoted by the oncogene KRAS, and KRAS mutations are prevalent in patients with PDAC. Therefore, a comprehensive understanding of the interactions between KRAS mutations and P...

Full description

Bibliographic Details
Main Authors: Fan Yang, Yanjie He, Nan Ge, Jintao Guo, Fei Yang, Siyu Sun
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Immunology
Subjects:
pancreatic ductal adenocarcinoma
KRAS mutations
risk prediction model
ferroptosis
immune microenvironment
potential drugs screening
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2023.1203459/full

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2023.1203459/full

Similar Items